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Platelet-Rich Plasma Attenuates 30 kDa Fibronectin Fragment 1 
Induced Chemokine and MMP Expression by Meniscocytes and 2 
Articular Chondrocytes  3 
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Abstract 4 
Background: Proteolytic fragments of fibronectin have catabolic effects on cartilage 5 
and menisci. Platelet-rich plasma (PRP) is increasingly being used in treatment of a 6 
range of joint pathologies but it is unknown whether PRP influences fibronectin 7 
fragment (FN-f) pro-catabolic activity. 8 
Hypotheses: The pro-catabolic activity of FN-f on meniscocytes and articular 9 
chondrocytes is attenuated by co-treatment with PRP. 10 
Study Design: Controlled laboratory study. 11 
Methods: Human meniscocytes were treated with FN-f (30 kDa) with/without PRP co-12 
incubation and gene expression analyzed by cDNA microarray analysis. Validation of 13 
altered expression of known and novel chemokine and protease genes was undertaken 14 
by real-time PCR in articular chondrocytes and meniscocytes.  Chemokine release was 15 
assayed by ELISA and intracellular pathway signaling was evaluated by western 16 
immunoblotting. 17 
Results: Microarray analysis and RT-PCR showed increased expression of MMP1, 18 
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MMP2, MMP3, MMP9, MMP13, IL-6 and IL-8 (CXCL8), CCL5, CCL20 and 19 
CXCL10 chemokines in meniscocytes following treatment with FN-f. Upregulation of 20 
these genes was significantly attenuated by PRP. Similar results were seen with 21 
articular chondrocytes although no change in MMP2 or MMP9 levels were identified. 22 
PRP induced suppression of gene expression was associated with activation of Akt and 23 
p44/p42.  24 
Conclusions：30 kDa FN-f induced expression of a range of pro-inflammatory 25 
chemokines and MMPs including IL-8, IL-6, CCL20, CCL5, CXCL10, MMP1, MMP3 26 
and MMP13 by both meniscocytes and articular chondrocytes is attenuated by PRP 27 
treatment. 28 
Clinical Relevance: These observations provide support for the use and further trials 29 
of PRP in management of cartilage and meniscal injuries.   30 
Keywords: platelet-rich plasma; fibronectin fragment; chondrocyte; chemokine; 31 
matrix metalloproteinase 32 
33 
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What is known about the subject:  34 
Proteolytic fragments of fibronectin are released from articular cartilage following 35 
impact injury and are increased in synovial fluid of patients with osteoarthritis (OA). 36 
These fibronectin fragments (FN-f) have catabolic activity inducing expression of a 37 
range of inflammatory mediators and proteases that contribute to both cartilage and 38 
meniscus degeneration. Removal of FN-f from OA synovial fluid decreases detrimental 39 
indicating that targeting these molecules may be of benefit in attenuating the 40 
development or progression of cartilage and meniscal pathology. There is increasing 41 
interest and application of platelet-rich plasma (PRP) for the treatment of osteoarthritis 42 
and a range of other joint and musculoskeletal conditions. PRP is a key source of 43 
molecules involved in tissue repair and regeneration and can deliver a variety of 44 
bioactive molecules that have the potential to suppress pro-inflammatory and 45 
proteolytic pathways. It is however not known whether PRP acts to inhibit the broad 46 
range of recognized and novel inflammatory and proteolytic pathways activated by 47 
FN-f in human meniscocytes and articular chondrocytes. 48 
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What this study adds to existing knowledge: 49 
In addition to confirming recent observations that FN-f increase expression of a range 50 
of matrix metallproteinases and chemokines in meniscocytes and articular 51 
chondrocytes we have, for the first time, identified that FN-f also increase expression 52 
of MMP9 and CCL5, CCL20 and CXCL10 chemokines in human meniscocytes. Co-53 
stimulation of both meniscocytes and articular chondrocytes with PRP significantly 54 
attenuated the FN-f increased expression of chemokines and MMPs providing 55 
mechanistic support for the use of intra-articular PRP injection for the treatment of 56 
degenerative and traumatic joint conditions including OA. 57 
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Introduction 58 
Fibronectin (FN) is a multidomain glycoprotein present in most extracellular matrices 59 
(ECM), including cartilage8 and synovium27, as a dimeric glycoprotein.  The dimeric 60 
glycoprotein is formed through a pair of anti-parallel disulfide bonds at the C terminus 61 
linking single glycoproteins with a molecular weight of 230–270 kDa.40 FN isoforms 62 
in adult cartilage are significantly different from fibronectins in other tissues and 63 
include predominantly the cartilage specific (V + C) isoform (50-80%) with smaller 64 
amounts of the of ED-B (+) isoform.9  Intact FN has important roles in matrix assembly, 65 
morphogenesis, cell migration and inflammation through the binding of multiple 66 
domains to itself and a range of matrix proteins and cell surface receptors including 67 
collagen, fibulin-1, syndecan and integrins.35 α5β1 integrin is the major FN receptor 68 
expressed by articular chondrocytes and has important roles in regulating chondrocyte 69 
responses to mechanical loading.33, 45, 58 70 
FN levels are elevated in cartilage in osteoarthritis (OA) as a result of increased 71 
production and retention.59 This increase of FN in OA cartilage is associated with an 72 
7 
 
increase in FN levels in synovial fluid.48 As well as being increased in amount, the FN 73 
in OA cartilage and synovium is fragmented, comprising FN-fragments (FN-f) of 30–74 
200 kDa.22 Unlike intact FN these FN-f have catabolic activity.21 FN-f bind to and 75 
penetrate cartilage tissue resulting in proteinase expression and cartilage damage.60 76 
FN-f show potent catabolic activity increasing expression of Toll-like receptors and 77 
inflammatory cytokines including TNF-α, IL-1β, and IL-1α, elevating production of 78 
matrix metalloproteinase(MMP) proteases, and suppressing proteoglycan synthesis.13, 79 
19, 20, 49, 51
 FN-f are also released from articular cartilage following impact injury7, and 80 
have been shown to increase production of MMPs by normal and OA meniscocytes in 81 
vitro50, indicating that a general increase in levels of these biologically active 82 
fragments in synovial fluid in OA or other joint pathologies is also detrimental to 83 
meniscus structure and function. 84 
Removal of FN-f from OA synovial fluid has been shown to diminish detrimental 85 
effects on cartilage22 indicating that targeting these molecules may be of benefit in 86 
attenuating the development or progression of cartilage and meniscal pathology. A 87 
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specific pharmacological agent that inhibits the catabolic effects of FN-f has not yet 88 
been developed but there is increasing interest in the use of biological therapies such as 89 
hyaluronan (HA) and platelet-rich plasma (PRP) for the treatment of osteoarthritis and 90 
a range of other joint and musculoskeletal conditions.15, 28, 29, 31, 38 91 
PRP is a key source of molecules involved in tissue repair and regeneration and can 92 
deliver a variety of bioactive molecules. These include a number of growth factors 93 
recognized to be important in regulation of chondrocyte proliferation and anabolic 94 
function including platelet-derived growth factor, transforming growth factor beta, 95 
fibroblast growth factor and insulin-like growth factor 1.5, 56 Delivery of a cocktail of 96 
agents, as is present in PRP, would be expected to be beneficial for repair of cartilage 97 
and meniscus injury and enhance tissue repair by stimulation of anabolic activity 98 
whilst proinflammatory and catabolic pathways would be inhibited.2, 26, 53 99 
The aim of this study was to assess whether PRP has inhibitory effects on expression of 100 
pro-inflammatory and proteolytic molecules induced by FN-f in human meniscocytes 101 
and articular chondrocytes. 102 
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Materials and Methods 103 
Human articular chondrocyte and meniscocyte isolation and culture 104 
Human cartilage and meniscus samples were obtained from surgical discard tissue, 105 
with consent (TMU-JIRB No.201305003), at knee joint arthroplasty from patients with 106 
OA (n = 43, mean age 72.86 years, range 56-84 years). Residual OA cartilage with 107 
predominantly grade II and III lesions (Collins/McElligot system) from each joint was 108 
removed and pooled. Cartilage and meniscus tissue were cut into small fragments, 109 
incubated with antimicrobial solution, containing 500 IU/mL penicillin (Gibco, 110 
Invitrogen, Burlington, Ontario, Canada), 500 mg/mL streptomycin (Gibco) and 2.5 111 
μg/mL Fungizone (Sigma, St Louis, MO, USA) for 4 h, and then washed with sterile 112 
phosphate-buffered saline (PBS) before digestion. Cells were extracted by sequential 113 
enzymatic digestion with 0.25% trypsin (Gibco) and collagenase type H (Sigma). 114 
Extracted cells were re-suspended in 10 mL Dulbecco’s modified Eagle’s 115 
medium/Nutrient Mixture F-12 HAM medium (Gibco) supplemented with 10% FBS 116 
(Gibco), 100 I.U./mL penicillin and 100 mg/mL streptomycin; seeded in complete 117 
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medium at a density of 5 x 105 cell/mL in 60 mm Petri dishes (TPP, Trasadingen, 118 
Switzerland); and cultured in a humidified 5% CO2 incubator at 37oC for further 119 
experimental procedures. Cells between passages 3 and 5 were used. 120 
Experimental protocol 121 
Human articular chondrocytes and meniscocytes were seeded at 5 × 105 cells/dish and 122 
grown as a monolayer for 5 days in 60 mm tissue culture Petri dishes. Cells were 123 
washed with sterile PBS twice, placed in serum-free media for 2 hours, and then co-124 
incubated with fibronectin proteolytic fragments 30 kDa at a concentration of 0.5 125 
μg/mL for 24 hours. Freeze-dried powder of PRP was prepared by Regen Lab and 126 
Regenkit (Regen Lab, Lausanne, Switzerland) by centrifugation of peripheral blood, 127 
using a thixotropic gel for cell separation and citrate as anticoagulant. The obtained 128 
PRP was approximately 3.3-fold platelet increase above baseline. Each ampoule of 129 
PRP was dissolved with 1 mL of distilled water. The concentrations of two major 130 
growth factors were - transforming growth factor-beta1 (TGF- β1) 125.9 pg/mL and 131 
platelet-derived growth factor (PDGF) 40.8 pg/mL. 80 μL of PRP solution was added 132 
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to cells with 2 mL medium to yield a final concentration of TGF- β1 5.036 pg/mL and 133 
PDGF 1.632 pg/mL.  134 
 135 
Extraction of RNA and Real-Time Polymerase Chain Reaction 136 
Total RNA was extracted using TRIzol® RNA Isolation Reagents (Invitrogen, NY, 137 
USA). For first-strand cDNA synthesis, 2 μg total RNA was used in a single-round 138 
reverse-transcription reaction by High-Capacity cDNA Reverse Transcription Kit 139 
(Applied Biosystems, Foster City, CA, USA). qPCR reactions were carried out in a 140 
final volume of 20 μL containing 1 μL of 20X TaqMan® Gene Expression Assay probe 141 
(Applied Biosystems), 10 μL of 2X TaqMan® Gene Expression Master Mix, 5 μL of 142 
RNase-free water, and 4 μL of cDNA. Complement DNAs were amplified with the 143 
following condition: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 144 
15 seconds and 60°C for 60 seconds, using a ViiA7 real-time PCR system (Applied 145 
Biosystems). Resultant cycle threshold (Ct) values were normalized to the endogenous 146 
control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and analyzed using the 147 
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2-∆∆Ct method. The Taqman Probes used for gene expression studies are listed in Table 148 
1.  149 
Microarray assay and data analysis 150 
RNA was extracted from control and cells incubated with 30 kDa FN-f`. 0.2 μg of total 151 
RNA was amplified by a Low Input Quick-Amp Labeling kit (Agilent Technologies, 152 
Palo Alto, CA, USA) and labeled with Cy3 (Agilent Technologies). 0.6 μg of Cy3-153 
labled cRNA was fragmented to an average size of 50-100 nucleotides by incubation 154 
with fragmentation buffer at 60°C for 30 minutes. Correspondingly fragmented labeled 155 
cRNA is then pooled and hybridized to Agilent SurePrint G3 Human V2 GE 8×60K 156 
Microarray (Agilent Technologies) at 65°C for 17 h.  After washing and drying by 157 
nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner at 158 
535 nm. Scanned images are analyzed by Feature extraction10.5.1.1 software (Agilent 159 
Technologies). The microarray data comply with MIAME (Minimum Information 160 
About a Microarray Experiment) guidelines, and the raw data have been deposited in a 161 
MIAME-compliant database. 162 
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Protein Extraction and Western blotting 163 
Following stimulation cells were immediately washed with ice-cold PBS and protein 164 
extracted with standard lysis buffer at 4°C for 15 min. Whole-cell lysates were 165 
collected after centrifugation at 13,000 rpm for 10 min. Equal amounts of protein were 166 
loaded onto 10% SDS-polyacrylamide gel and following electrophoresis were 167 
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Membranes 168 
were blocked overnight at 4°C with 2% BSA in TBST (12.5 mM Tris/HCl, pH 7.6, 137 169 
mM NaCl, 0.1% Tween 20). After washing with TBST, blots were incubated at 4°C 170 
overnight with primary antibodies (PathScan® Multiplex Western Cocktail I 1/1000; 171 
p44/42 MAPK 1/1000; AKT 1/1000) (all from Cell Signaling Technology, MA, USA) 172 
diluted in TBST respectively, washed 6 times before incubation with HRP-labeled 173 
secondary antibody 1/5000 (DakoCytomation, Copenhagen, Denmark) for 1 h at room 174 
temperature. Membranes were rewashed extensively and antibody binding was 175 
visualized with Immobilon™ Western HRP Substrate (Millipore). Immunoblots were 176 
scanned by a UVP BioSpectrum AC image system (UVP, Upland, CA, USA) and 177 
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quantitated using VisionWork LS software (UVP). Anti-alpha-tubulin (1/5000; Abcam, 178 
Cambridge, UK) acted as internal control.  179 
ELISA 180 
Quantification of IL-8 (CXCL8) in supernatants of cultured medium was carried out 181 
using Quantikine ELISA kits (R&D Systems, Minneapolis, USA).   182 
Statistical analysis 183 
The values were expressed as fold of band intensity of the target gene or protein to the 184 
internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene or alpha-185 
tubulin. The results are expressed as the mean ± SD. Data are analyzed using SPSS 186 
(Statistical Package for Social Sciences) statistical software 18.0; all statistical tests use 187 
Student's t-test, and the p value < 0.05 is considered statistically significant.  188 
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Results 189 
PRP attenuates FN-f induced chemokine gene expression in meniscocytes and 190 
articular chondrocytes 191 
Microarray analysis 192 
To investigate the global gene change in meniscocytes as a result of stimulation with 193 
0.5 μg/mL 30 kDa FN-f an initial microarray assay was carried out. Analysis using the 194 
GeneSpring GX software showed that expression of 258 genes was significantly 195 
altered. Novel findings were the upregulation of several chemokine genes. The top 5 196 
upregulated genes were IL-8 (CXCL8), CCL20, IL-6, CXCL10, and CCL5, 197 
respectively (Table 2). To assess whether PRP had any effect on the 30 kDa FN-f 198 
induced changes in gene expression meniscocytes were co-incubated with PRP and 30 199 
kDa FN-f. With co-incubation there was a significant downregulation of expression of 200 
each of these top 5 upregulated genes rather than the increased expression seen with 201 
FN-f treatment alone (Table 2).  202 
Quantitative gene expression 203 
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To confirm these results and to establish whether similar effects were seen in articular 204 
chondrocytes experiments were undertaken in which changes in gene expression were 205 
assessed by Q-PCR. Following 24 hours incubation with 30 kDa FN-f expression of 206 
IL-8 (410.1 ± 310.9 fold), CCL20 (287.8 ± 50.3 fold), IL-6 (281.0 ± 199.4 fold), 207 
CXCL10 (859.9 ± 665.2 fold), and CCL5 (167.7 ± 90.4 fold) was significantly 208 
increased in meniscocytes. These changes were attenuated by co-treatment with PRP 209 
for each of the 5 genes: IL-8 (18.1 ± 13.7 fold, p = 0.042); CCL20 (14.5 ± 11.5 fold, p 210 
= 0.0008); IL-6 (12.7 ± 7.8 fold, p = 0.0362); CXCL10 (6.2 ± 5.6 fold, p = 0.0448); 211 
CCL5 (2.9 ± 2.1 fold, p = 0.011) (Figure 1A). 30 kDa FN-f also significantly 212 
upregulated expression of IL-8, CCL20, IL-6, CXCL10, and CCL5 in articular 213 
chondrocytes (164.4 ± 78.2 fold, p = 0.0095; 122.6 ± 76.34 fold, p = 0.0014; 43.8 ± 214 
22.9 fold, p = 0.033; 186.7 ± 140.4 fold, p = 0.042; 14.29 ± 11.27 fold, p = 0.003, 215 
respectively). These changes were significantly attenuated by co-treatment with PRP 216 
(IL-8 - 25.3 ± 22.1 fold, p = 0.005; CCL20 - 18.7 ± 9.5 fold, p = 0.0009; IL-6  - 10.7 ± 217 
7.9 fold, p = 0.034; CXCL10 - 8.6 ± 4.9 fold, p = 0.044, and CCL5 - 2.4± 1.9 fold, p = 218 
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0.003, respectively) (Figure 1B). With PRP treatment alone there was no significant 219 
change in expression of IL-8, CCL20, IL-6, CXCL10, and CCL5 genes in either 220 
meniscocytes or articular chondrocytes over the time period tested. 221 
 222 
PRP reduces FN-f induced IL-8 secretion by meniscocytes and articular 223 
chondrocytes  224 
IL-8 secretion by primary meniscocytes was significantly increased following 30 kDa 225 
FN-f stimulation for 24 hours (603.59 ± 594.81 vs 112.8 ± 32.3 pg/mL, p = 0.0037) 226 
(Figure 2A). This enhanced production was significantly suppressed by PRP co-227 
incubation (266.38 ± 214.09 pg/mL, p = 0.0087) (Figure 2A). Treatment with PRP 228 
alone had no significant effect on basal IL-8 secretion levels (128.37 ± 51.29 vs 112.8 229 
± 32.3 pg/mL, p = 0.0583). 30 kDa FN-f had similar but more pronounced effects on 230 
articular chondrocytes showing a significant increase in IL-8 secretion following 231 
stimulation for 24 hours (5672.86 ± 5266.53 vs 155.15 ± 52.37 pg/mL, p = 0.0026). 232 
The increased secretion of IL-8 induced by 30 kDa FN-f was significant suppressed by 233 
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PRP but remained above basal levels (1049.26 ± 866.66 pg/mL, p = 0.0024) (Figure 234 
2B). There was a small, but non-significant increase in IL-8 levels when articular 235 
chondrocytes were incubated with PRP alone (237.14 ± 97.45 vs 155.15 ± 52.37 236 
pg/mL, p = 0.0523).  237 
FN-f induced MMP expression by meniscocytes and articular chondrocytes is 238 
inhibited by PRP  239 
Following incubation of meniscocytes with 30 kDa FN-f for 24 hours gene expression 240 
of MMP1, MMP2, MMP3, MMP9, and MMP13 was significantly increased (112.7 ± 241 
58.0 fold; 1.9 ± 0.4 fold; 41.7 ± 22.0 fold; 1.7 ± 0.3 fold; 15.6 ± 2.2 fold, respectively). 242 
Co-incubation with PRP significantly attenuated the effect of 30 kDa FN-f on MMP1, 243 
MMP2, MMP3 and MMP13 gene expression (6.6 ± 4.2 fold; 1.0 ± 0.2 fold; 3.4 ± 2.0 244 
fold; 2.3 ± 1.3 fold, respectively). MMP9 gene expression was also decreased by co-245 
incubation with PRP but the results did not reach statistical significance. There was no 246 
change in gene expression of MMP1, MMP2, MMP3, MMP9, and MMP13 in 247 
meniscocytes cultured for 24 hours in PRP alone (Figure 3A).  248 
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Articular chondrocyte expression of MMP1, MMP3 and MMP13 genes was 249 
significantly upregulated by incubation with 30 kDa FN-f (17.6 ± 11.3 fold; 29.2 ± 250 
18.3 folds; 6.3 ± 5.7 fold, respectively). This effect was significantly attenuated by co-251 
treatment with PRP (3.4 ± 1.9 fold; 4.3 ± 3.1 fold; 2.4 ± 0.6 fold, respectively). In 252 
contrast to meniscocytes, MMP2 and MMP9 genes expression was not upregulated by 253 
30 kDa FN-f stimulation. MMP1, 2, 3, 9, and 13 showed no significant gene regulation 254 
following PRP treatment alone (Figure 3B). 255 
Akt and p44/42 MAP kinase phosphorylation induced by PRP 256 
To investigate potential mechanisms by which PRP may be influencing chemokine and 257 
MMP gene expression we looked at the activation of Akt and p44/42 MAP kinase, both 258 
molecules being recognized as important regulatory intracellular signaling pathways in 259 
chondrocytes and meniscocytes. Following stimulation with PRP Akt phosphorylation 260 
was rapidly increased in meniscocytes and maintained for up to 3 hours (16.63 ± 5.28 261 
fold, p = 0.0096 at 0.5 h; 10.47 ± 1.94 fold, p = 0.0023 at 1 h; 4.74 ± 2.42 fold, p = 262 
0.0533 at 3 h; compared to baseline). p44/42 phosphorylation was similarly increased 263 
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over the same time course (5.24 ± 1.23 fold, p = 0.0015 at 0.5 h; 3.66 ± 0.95 fold, p = 264 
0.0033 at 1 h; 4.54 ± 2.29 fold, p = 0.0258 at 3 h, compared to baseline). Under 265 
identical conditions similar results were seen when articular chondrocytes were 266 
incubated with PRP (Figure 4). Phosphorylation of Akt was increased at each time 267 
point (0.5 h = 19.01 ± 5.30 fold, p = 0.0016; 1 h = 21.26 ± 4.45 fold, p = 0.0005; 3 h = 268 
12.47 ± 5.91 fold, p = 0.0122, compared to baseline). Phosphorylation of p44/42 MAP 269 
kinase followed an analogous pattern (0.5 h = 3.58 ± 2.06 fold, p = 0.0487, 1 h = 3.33 270 
± 2.62 fold, p = 0.1175, 3 h = 2.67 ± 2.47 fold, p = 0.204, compared to baseline). 271 
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Discussion 272 
In this study we aimed to assess the influence of PRP on FN-f induced pro-273 
inflammatory and proteolytic activity of human meniscocytes and articular 274 
chondrocytes. Using a gene microarray we have identified that 30-kDa FN-f induces 275 
increased gene expression of several chemokines in meniscocytes and chondrocytes. In 276 
addition to confirming observations that FN-f increases expression of MMP1, MMP2, 277 
MMP3, MMP13, IL-6 and IL-8 in meniscocytes50 we have, for the first time, identified 278 
that FN-f also increases expression of MMP9 and CCL5, CCL20 and CXCL10 279 
chemokines in human meniscocytes. Similar effects are evident in articular 280 
chondrocytes although we found no change in MMP2 or MMP9 expression in these 281 
cells consistent with findings by others.49 Importantly, co-stimulation of both 282 
meniscocytes and articular chondrocytes with PRP significantly attenuated the FN-f 283 
increased expression of chemokines and MMPs.  284 
Currently 44 human chemokine ligands 21 chemokine receptors have been described. 285 
Chemokine receptors contain 7 transmembrane domains and are G protein-coupled.42 286 
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Whilst chemokines act as critical extracellular mediators of cell migration, particularly 287 
in the immune system34 there is increasing interest in potential roles as inflammatory 288 
mediators in joint tissues. Chondrocytes and meniscocytes express numerous CC and 289 
CXC chemokines, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL11 (eotaxin-1), 290 
CXCL1, CXCL2, CXCL3, IL-8 (CXCL8), in addition to a number of chemokine 291 
receptors which potentially play important roles in activating catabolic pathways.23, 47, 292 
50
 The pattern of chemokine and chemokine receptor expression in normal and OA 293 
chondrocytes suggests that chemokines have an impact in cartilage homeostasis and 294 
release of matrix-degrading enzymes in normal cartilage remodeling and cartilage 295 
breakdown.11  Chemokine levels are increased in synovial fluid in patients with 296 
osteoarthritis.18 Chemokine and chemokine receptor expression is also elevated in 297 
damaged menisci6 indicating that chemokine production in cartilage or meniscus due to 298 
biomechanical injury is important in the development of degenerative joint disease.7  299 
Our observation that meniscocytes, in addition to chondrocytes, express CCL5, CCL20 300 
and CXCL10 chemokines and that expression of these cytokines is increased in 301 
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articular chondrocytes and meniscocytes on exposure to the proinflammatory 30 kDa 302 
FN-f is novel. The effect of increased expression of these chemokines in cartilage and 303 
menisci is not yet clear. Whilst IL-1β and high-mobility group protein 1 (HMGB1) 304 
increase expression of CCL5, CCL20 and CXCL10 chemokines in human 305 
chondrocytes, expression of CCL5 is decreased by the chondroprotective cytokine IL-4 306 
indicating likely roles as pro-inflammatory mediators in the OA. 1, 3, 39 307 
Cartilage breakdown results in production of metabolically active breakdown products 308 
such as FN-f. It is likely, although not yet confirmed that FN-f can also be produced in 309 
menisci following acute or chronic degeneration and have effects on all intra-articular 310 
tissues. Meniscocytes express a range of MMPs including MMP1, MMP2, MMP3, 311 
MMP8, MMP9 and MMP13.32 Levels of MMPs in synovial fluid are elevated rapidly 312 
in patients with a meniscal injury and remain elevated for at least 20 years post 313 
injury.30 Targeting MMP activity within the joint may prevent long-term damage. Pro-314 
catabolic FN-fs appear to act predominantly through the α5β1 integrin receptor.57 Thus, 315 
it would be possible to attempt to influence FN-f activity through targeting this 316 
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receptor. However, as single agent therapies are increasingly found to be ineffective 317 
there is interest in more broad based biological approaches to treating joint injury and 318 
osteoarthritis, especially in its early phase. Targeting pathways activated by FN-f may 319 
be an effective means of inhibiting production of multiple mediators of cartilage 320 
destruction.43  321 
Autologous PRP injections were first used in 1987 in open heart surgery.14 As a low 322 
cost and minimally invasive way to obtain a natural concentration of autologous 323 
growth factors, PRP is being studied in different fields of medicine for its ability to aid 324 
tissue regeneration.12,16 PRP has been shown to enhance the healing of meniscal defects 325 
in a rabbit model.24 Preclinical studies showing that PRP enhances chondrocyte 326 
viability, proliferation and matrix production provide mechanistic support for the use of 327 
intra-articular PRP injection.25, 36 The optimal concentration, composition and relative 328 
importance of each of the components of PRP for clinical use remain unclear. Platelet 329 
concentrations of 2.5-3 fold above baseline are considered to be ideal, with higher 330 
concentrations potentially inhibiting tissue healing.17, 46, 55 Furthermore the “ideal” 331 
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platelet concentration may depend on the target parameter (e.g., direct promotion of 332 
tissue healing or stem cell recruitment), the tissue being treated (e.g., bone, cartilage, or 333 
tendon), and stage of disease or wound healing. Consequently, the “ideal” platelet 334 
concentration for various clinical scenarios remains unknown. PRP concentration can 335 
vary considerably depending on an individual’s blood platelet levels from day to day, 336 
diet, general health, medication and exercise. The method of PRP preparation also 337 
influences platelet concentration and levels of growth factors. PRP used in treatment of 338 
osteoarthritis usually contains between 2-6 fold normal platelet concentrations41 339 
although the optimal protocol for PRP injection in knee OA has not been defined. PRP, 340 
approximately 6.8 fold above baseline, inhibits the inflammatory processes in human 341 
osteoarthritic chondrocytes53 whilst a double-blinded, randomized controlled trial using 342 
PRP with a platelet concentration of approximately 3 fold above baseline showed 343 
benefit over placebo.37 Other randomized controlled trials have also shown that PRP 344 
injection, although with variable preparation formulae, provides symptomatic relief in 345 
early knee OA37, a significantly better clinical outcome compared with HA treatment 346 
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in grade III gonarthrosis10 and efficacy in management of pain and inflammation in 347 
OA.2, 26 The commercially available PRP preparation we used had a platelet 348 
concentration of 3.3 fold and is within the ‘therapeutic range’. The preparation 349 
contained 125.9 and 40.8 pg/mL of TGF-β1 and PDGF respectively which, at the final 350 
concentration used in our experimental model system, are at a level at which they 351 
would be expected to be biologically active.44 . In the current study the levels of Akt 352 
and p44/42 MAP kinase phosphorylation rapidly increase in both meniscocytes and 353 
articular chondrocytes upon incubation with PRP. This is in line with the published 354 
literature on Akt and p44/42 MAP kinase phosphorylation following incubation of 355 
chondrocytes with a range of growth factors and cytokines.4 356 
We have shown that PRP can attenuate the effects of FN-f on both chondrocyte and 357 
meniscocyte production of pro-catabolic chemokines and MMPs. The mechanisms by 358 
which these effects are produced are not clear but are likely to be multifactorial as PRP 359 
can potentially affect numerous overlapping pathways simultaneously due to the 360 
presence of a number of anti-inflammatory cytokines and anabolic growth factors.2 361 
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Interestingly PRP has been shown to stimulate endogenous HA production and show 362 
similar effects to HA in the suppression of inflammatory gene and protein expression 363 
in synoviocytes and cartilage.52 High-molecular-weight (800 kDa) HA is believed to be 364 
effective in vitro and in vivo in blocking the catabolic action of FN-f by preventing 365 
entry of the fragments into the cartilage.54 A recent in vitro study comparing the 366 
activity of HA and PRP on the expression of anabolic and catabolic genes and 367 
inflammatory mediators from human OA cartilage and synoviocytes indicated that 368 
whilst both agents decreased catabolic activity, PRP treatment also caused a significant 369 
reduction of MMP13, an increase in HAS-2 expression in synoviocytes and an increase 370 
in cartilage synthetic activity compared with HA.52 371 
28 
 
Conclusion 372 
In the current study, 30 kDa FN-f induced production of a range of chemokines and 373 
MMPs including IL-8, IL-6, CCL20, CCL5, CXCL10, MMP1, MMP3 and MMP13 374 
by both meniscocytes and articular chondrocytes was attenuated by PRP treatment. 375 
These observations suggest the mechanism by which PRP might help osteoarthritis 376 
and suggests a rationale for continued limited clinical trials. Variations in the 377 
composition of PRP from patient to patient are however recognized and composition 378 
may also vary depending on the device and protocols used for preparation, methods 379 
and time of storage. Due to these limitations and questions remaining on potential 380 
interactions with other biologics or materials the current use of PRP in orthopedics 381 
needs to be further established. 382 
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Table 1. Taqman Probes used for Gene Expression Studies. 569 
GeneSymbol Accession No. Applied Biosystems Order No. 
IL-6 NM_000600 Hs00174131_m1 
IL-8 NM_000584 Hs00174103_m1 
CXCL10 NM_001565 Hs00171042_m1 
CCL5 NM_002985 Hs00174575_m1 
CCL20 NM_004591 Hs00355476_m1 
MMP1 NM_002421 Hs00233958_m1 
MMP2 NM_004530 Hs01548727_m1 
MMP3 NM_002422 Hs00968305_m1 
MMP9 NM_004994 Hs00234579_m1 
MMP13 NM_002427 Hs00233992_m1 
GAPDH NM_002046 Hs02758991_g1 
 570 
Table 2. Top of 5 upregulated genes (ranking 1-5) by 30 kDa FN-f stimulation and 571 
downregulated chemokine genes by PRP treatment in meniscocytes. 572 
Upregulated genes Downregulated genes 
Ranking GeneSymbol
 
Log Ratio (2)
 
Ranking
 
GeneSymbol
 
Log Ratio (2)
 
1
 
IL-8
 
9.358
 
1 CXCL10 -7.523 
2
 
CCL20
 
8.750
 
4 CCL5 -5.121 
3
 
IL-6
 
7.563
 
8 CCL20 -4.464 
4
 
CXCL10
 
7.412
 
16 IL-8         -3.951 
5
 
CCL5
 
6.545
 
17 IL-6 -3.830 
573 
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Figure legends 574 
Figure 1. Validation of microarray analysis in both (A) meniscocytes and (B) articular 575 
chondrocytes. Top 5 upregulated genes including IL-8, CCL20, IL-6, CXCL10, and 576 
CCL5 induced by 30 kDa FN-f all showed significant downregulation by the treatment 577 
of PRP. (＊p < 0.05, compared with control; ＊＊p < 0.01, compared with control; 578 
#p<0.05, 30 kDa+PRP vs 30 kDa). 579 
 580 
Figure 2. Effects of PRP on 30 kDa FN-f induced IL-8 release. (A) IL-8 release 581 
induced by 30 kDa FN-f was suppressed by PRP treatment in meniscocytes. (B) 582 
Similar effect was seen in articular chondrocytes. (＊＊p<0.01, compared with control; 583 
#p<0.05, 30 kDa+PRP vs 30 kDa). 584 
 585 
Figure 3. Effects of PRP on 30 kDa FN-f induced MMP expression in both (A) 586 
meniscocytes and (B) articular chondrocytes. Upregulation of MMPs induced by 30 587 
kDa FN-f was suppressed by the treatment of PRP in meniscocytes. In articular 588 
chondrocytes MMP1, MMP3, and MMP13 gene expression showed the similar pattern. 589 
There was no significant change in MMP2 and MMP9 gene expression in articular 590 
chondrocytes. (＊p<0.05, compared with control; #p<0.05, 30 kDa+PRP vs 30 kDa ). 591 
 592 
Figure 4. Protein phosphorylation of Akt and p44/42 by PRP treatment in human 593 
meniscocytes (A) and articular chondrocytes (B). Left panel - representative blots ;  594 
right panel - semiquantitative data. Rapid protein phosphorylation of Akt and p44/42 595 
was recognized in both cell types. (＊p<0.05, compared with control; ＊＊p<0.01, 596 
compared with control; ＊＊＊p<0.001, compared with control). 597 




